Arcede Pharma develops the drug candidate RCD405, focused on the treatment of chronic obstructive pulmonary disease (COPD). The candidate has a dual mechanism of action that is both bronchodilator and anti-inflammatory, opening up the possibility of not only treating the symptoms but also affecting the underlying causes of the disease.
After completing toxicological studies with promising results, Arcede Pharma is now preparing for Phase I clinical trials, scheduled to start in late 2024.
CEO Mia Lundblad resigns
Now the company's CEO announces Mia Lundblad that she will resign, as she has been offered a more research-oriented position outside the company, which she could not refuse. The board has therefore decided to appoint the current CFO as of February 1, 2024 Erik Magnusson to acting CEO at the same time as Chairman of the Board Ingemar Kihlstrom takes on the role of working chairman.
"RCD405 is an incredibly exciting project with great potential, but I am choosing to stop in order to focus more on the research and drug development role itself, which I have greater knowledge and understanding of.", writes Mia Lundblad in a press release.
Chairman of the Board Ingemar Kihlstrom comments on Lundblad's departure: "During her time as CEO, Mia Lundblad has carried out many valuable tasks with the development of RCD405, including ensuring that the preclinical documentation prior to the start of phase I is completed, as well as establishing external collaborations with, for example, KI and Lund University to understand the pharmacological mechanism of action."
Kihlström further comments on the appointment of Erik Magnusson as acting CEO: "Erik has extensive knowledge of life science for more than 25 years, from both large and small companies. He has great work capacity and I warmly welcome him to this assignment."